Incubate Bio

Our mission is to develop in silico data packages containing characterized and prioritized targets & biomarkers with critical evidence, for outlicensing to biotech and biopharma.  We have bespoke technology that identifies key pathway drivers and supports indication expansion, patient stratification, synthetic lethality and combination therapies.  The technology is also being used as a cost-effective service to provide credible in silico data to support pre-clinical biological asset value, to generate new evidence around targets and to support biotech fundraising.

For more about our software platform and recent results: 

https://www.incubate.bio/alasca
https://www.incubate.bio/askmaddy